Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"

NCT07021677 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
18
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Tata Memorial Centre